Bank of America Corp DE reduced its position in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) by 38.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,862,330 shares of the biotechnology company's stock after selling 1,790,995 shares during the quarter. Bank of America Corp DE owned 1.12% of Adaptimmune Therapeutics worth $1,540,000 at the end of the most recent quarter.
Several other large investors also recently added to or reduced their stakes in ADAP. Invesco Ltd. boosted its holdings in shares of Adaptimmune Therapeutics by 82.0% during the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company's stock worth $34,000 after purchasing an additional 28,526 shares during the period. Virtu Financial LLC lifted its position in Adaptimmune Therapeutics by 21.5% in the 4th quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company's stock worth $66,000 after buying an additional 21,688 shares in the last quarter. LPL Financial LLC lifted its position in Adaptimmune Therapeutics by 106.5% in the 4th quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company's stock worth $99,000 after buying an additional 94,623 shares in the last quarter. Jane Street Group LLC boosted its stake in shares of Adaptimmune Therapeutics by 87.7% during the 4th quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company's stock valued at $176,000 after buying an additional 152,780 shares during the period. Finally, Rock Springs Capital Management LP grew its holdings in shares of Adaptimmune Therapeutics by 2.4% during the 4th quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company's stock valued at $1,338,000 after acquiring an additional 58,000 shares in the last quarter. 31.37% of the stock is owned by institutional investors and hedge funds.
Adaptimmune Therapeutics Stock Performance
Shares of ADAP stock traded down $0.00 during trading on Friday, reaching $0.28. The company had a trading volume of 873,615 shares, compared to its average volume of 1,716,560. The firm's 50 day simple moving average is $0.27 and its two-hundred day simple moving average is $0.46. Adaptimmune Therapeutics plc has a one year low of $0.20 and a one year high of $1.48. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. The company has a market capitalization of $75.01 million, a PE ratio of -1.29 and a beta of 2.86.
Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.18) EPS for the quarter, meeting analysts' consensus estimates of ($0.18). The company had revenue of $7.29 million for the quarter, compared to analyst estimates of $6.55 million. Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. Sell-side analysts forecast that Adaptimmune Therapeutics plc will post -0.14 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of analysts recently issued reports on ADAP shares. HC Wainwright reduced their price objective on Adaptimmune Therapeutics from $3.50 to $3.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Guggenheim reduced their price target on Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating for the company in a report on Wednesday, March 26th. Wells Fargo & Company lowered their price target on Adaptimmune Therapeutics from $1.50 to $1.00 and set an "equal weight" rating for the company in a research note on Wednesday, May 14th. Barclays cut their price objective on shares of Adaptimmune Therapeutics from $1.00 to $0.46 and set an "underweight" rating on the stock in a research report on Wednesday, May 14th. Finally, Scotiabank decreased their target price on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating for the company in a research report on Friday, March 21st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $1.52.
Get Our Latest Stock Report on ADAP
About Adaptimmune Therapeutics
(
Free Report)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
Further Reading
Before you consider Adaptimmune Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptimmune Therapeutics wasn't on the list.
While Adaptimmune Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
